Log in to save to my catalogue

First-in-human study of 99mTc-labeled fucoidan, a SPECT tracer targeting P-selectin

First-in-human study of 99mTc-labeled fucoidan, a SPECT tracer targeting P-selectin

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_34a2387182cc4b73afcd6d215acffb5e

First-in-human study of 99mTc-labeled fucoidan, a SPECT tracer targeting P-selectin

About this item

Full title

First-in-human study of 99mTc-labeled fucoidan, a SPECT tracer targeting P-selectin

Publisher

Berlin/Heidelberg: Springer Berlin Heidelberg

Journal title

EJNMMI research, 2024-11, Vol.14 (1), p.112-9, Article 112

Language

English

Formats

Publication information

Publisher

Berlin/Heidelberg: Springer Berlin Heidelberg

More information

Scope and Contents

Contents

Background
Activation of endothelial cells and platelets in atherothrombosis is characterized by upregulation of P-selectin. As a consequence, P-selectin represents a potential target for molecular imaging to identify thrombosis at an early stage. Fucoidan is a polysaccharide ligand extracted from brown algae with nanomolar affinity for P-selectin. This first-in-human study evaluated in healthy volunteers the safety, whole-body biodistribution, and dosimetry of
99m
Tc-fucoidan (Good Manufacturing Practices grade). We also investigated whether we could observe binding of
99m
Tc-fucoidan to human thrombi ex vivo and in vivo. In ten healthy volunteers, conjugate whole-body scans were performed up to 24 h following intravenous injection of
99m
Tc-fucoidan (370 MBq). Moreover,
99m
Tc-fucoidan uptake in ex vivo human thrombi (n = 11) was measured by gamma counting. Additionally, three patients with a newly diagnosed deep vein thrombosis (DVT) were subjected to
99m
Tc-fucoidan SPECT/CT imaging.
Results
99m
Tc-fucoidan was well tolerated in all participants without any drug-related adverse events. The total-body absorbed dose in males was comparable to females (0.012 ± 0.004 vs. 0.011 ± 0.005 mSv/MBq;
p
 = 0.97). Gamma counting experiments demonstrated binding of tracer to ex vivo human thrombi that was 16% lower after blocking with a natural P-selectin ligand, Sialyl Lewis X.
99m
Tc-fucoidan demonstrated specific uptake at the thrombus site in one out of three scanned patients with DVT.
Conclusions
99m
Tc-Fucoidan has a favorable biodistribution and safety profile.
99m
Tc-fucoidan exhibited specific binding to human thrombi in both in vivo and ex vivo settings. Nonetheless, the in vivo results do not support further clinical investigation of
99m
Tc-fucoidan as an imaging modality for DVT. Other clinical implementations of a technetium− 99m-labeled P-selectin tracer should be considered.
Trial registration
: Clinicaltrials,NCT03422055.Registered 01/15/2018. URL:
https://clinicaltrials.gov/study/NCT03422055
Landelijk Trial Register, NL7739. Registered 4/2/2019 .
https://onderzoekmetmensen.nl/en/trial/26785...

Alternative Titles

Full title

First-in-human study of 99mTc-labeled fucoidan, a SPECT tracer targeting P-selectin

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_34a2387182cc4b73afcd6d215acffb5e

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_34a2387182cc4b73afcd6d215acffb5e

Other Identifiers

ISSN

2191-219X

E-ISSN

2191-219X

DOI

10.1186/s13550-024-01173-8

How to access this item